Reported 3 days ago
Abbott Laboratories has upheld its annual profit forecast while planning to invest $500 million in U.S. manufacturing and research, despite tariff uncertainties. The company reported a first-quarter profit of $1.09 per share, surpassing Wall Street's expected $1.07, fueled by robust sales in its glucose monitoring products, which increased by 18.3% year-over-year. Abbott aims to launch new projects in Illinois and Texas by year-end, marking its commitment to navigating trade challenges.
Source: YAHOO